Calistoga Pharmaceuticals
Developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD580m (Public information from Feb 2011)
Seattle Washington (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$21.0m | Series A | ||
$5.2m | Series A | ||
N/A | $1.0m | Series A | |
$30.0m | Series B | ||
$40.0m | Series C | ||
$375m Valuation: $375m | Acquisition | ||
Total Funding | AUD150m |
Related Content
Recent News about Calistoga Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.